There has been some selling insider activity on United Therapeutics Corporation (NASDAQ:UTHR) recently. Christopher Patusky, Director reported the sale of 5,000 shares. The shares were purchased at an average price of $122.73. The Director now owns $0 of the stock according to the SEC filing. Today Martine A. Rothblatt, Chairman disclosed the sale of 1,293 shares of (UTHR). The shares were sold on July 7th for an average price of $110.02. Rothblatt now owns $15,403 of the stock per the Form 4 SEC filing.
Tommy G. Thompson, Director sold $231,240 worth of shares at an average price of $115.62 on Wed the 8th. That brings Thompson’s holdings to $0 per an SEC filing yesterday.
Here are some other firms who have updated their holdings. As of the end of the quarter BNP Paribas Investment Partners S.A. had disposed of a total of 16,623 shares trimming its stake by 88.2%. The value of the investment in United Therapeutics Corporation decreased from $2,953,000 to $236,000 a change of 92.0% quarter over quarter. As of quarter end Twin Tree Management, Lp had sold 3,400 shares trimming its position 89.5%. The value of the total investment in United Therapeutics Corporation went from $489,000 to $63,000 decreasing 87.1% quarter to quarter.
Nomura Holdings Inc cut its investment by shedding 2,090 shares a decrease of 49.3%. Nomura Holdings Inc owns 2,149 shares valued at $227,000. The total value of its holdings decreased 52.6%. As of the end of the quarter Northwestern Mutual Investment Management Company, LLC had sold a total of 122 shares trimming its holdings by 1.6%. The value of the company’s investment in United Therapeutics Corporation went from $872,000 to $816,000 a change of $56,000 since the last quarter.
On June 15 the stock rating was downgraded from “” to “Neutral” with a current price target of $95.00 in a report issued by H.C. Wainwright. On May 24 the company was downgraded to “Hold” from “Buy” in a statement from Argus Research.
On April 29, 2016 the stock rating was rated “Neutral” according to a Ladenburg Thalmann report which was a cut from the previous “” rating. On February 26 Barclays made no change to the company rating of “Equal-weight” but moved down the price target to $145.00 from $155.00.
On February 10 the company was upgraded from “Hold” to “Buy” and a price target of $148.00 was set in a report from Standpoint Research. August 19 investment analysts at Wedbush kept the company rating at “Outperform” but raised the price target from $209.00 to $244.00.
The company is trading down from yesterday’s close of $125.57. Shares of the company are trading at $122.01 which is a tad under $124.29, the stock’s 50 day moving average and which is slightly above the 200 day moving average of $116.01. The 50 day moving average moved down $-2.28 and the 200 day average was up $6.00.
The company’s P/E ratio is 5.90 and the market value is 5.30B. In the latest earnings report the EPS was $20.68 and is estimated to be $15.82 for the current year with 43,467,000 shares presently outstanding. Analysts expect next quarter’s EPS to be $3.42 with next year’s EPS anticipated to be $13.73.
Investors are feeling more bullish on United Therapeutics Corporation recently as indicated by the change in short interest. The company experienced a fall in short interest of -0.02% as of the latest report on September 15, 2016. Short interest fell from 7,626,190 to 7,437,673 over that timeframe. The short-interest ratio decreased to 14.7 and the percentage of shorted shares was 0.17% on September 15.